What is NETSPOT (Gallium-68)?
NETSPOT is the first Gallium-68 injection, a radioactive diagnostic agent for PET/CT imaging. This scan helps accurately locate and characterize tumors in adult patients with somatostatin-receptor positive Neuroendocrine Tumors (NETs).
Gallium-68 dotatate (NETSPOT) is a new FDA-approved radiopharmaceutical test that makes Neuroendocrine Tumors visible on medical images for the purpose of accurate diagnosis and tracking.
What are Neuroendocrine Tumors?
Neuroendocrine Tumors (NETs) are a group of uncommon tumors. There are several types of NETs, but most occur throughout the gastrointestinal tract and lungs. They have become the second most common cancer of the gastrointestinal tract.
Symptoms often resemble those of other diseases, like sweating, diarrhea, abdominal pain, and GI bleeding. This can lead to delays in diagnosis or even misdiagnosis and inappropriate treatment. However, advances in treatment have made it possible for more and more patients to be accurately diagnosed, seek the most appropriate treatment, and live with the disease.